AU Stock MarketDetailed Quotes

CU6 Clarity Pharmaceuticals Ltd

Watchlist
  • 7.200
  • +0.190+2.71%
20min DelayMarket Closed Nov 8 16:00 AET
2.31BMarket Cap-46451P/E (Static)

Clarity Pharmaceuticals Ltd Key Stats

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Jun 30, 2024
(FY)Jun 30, 2023
(FY)Jun 30, 2022
Total revenue
Cost of revenue
Gross profit
Operating expense
55.70%56.31M
19.39%36.16M
30.29M
Selling and administrative expenses
170.43%5.48M
-77.67%2.03M
--9.07M
-General and administrative expense
170.43%5.48M
-77.67%2.03M
--9.07M
Research and development costs
45.53%45.78M
66.45%31.46M
--18.9M
Depreciation amortization depletion
52.29%153.07K
117.33%100.51K
--46.25K
-Depreciation and amortization
52.29%153.07K
117.33%100.51K
--46.25K
Other operating expenses
89.74%4.89M
13.32%2.58M
--2.28M
Operating profit
-55.70%-56.31M
-19.39%-36.16M
-30.29M
Net non-operating interest income (expenses)
48.66%2.77M
1,860.46%1.86M
95.09K
Non-operating interest income
48.66%2.77M
1,860.46%1.86M
--95.09K
Other net income (expenses)
17.41%11.51M
51.74%9.8M
6.46M
Other non-operating income (expenses)
17.41%11.51M
51.74%9.8M
--6.46M
Income before tax
-71.55%-42.03M
-3.21%-24.5M
-23.74M
Income tax
186.00%295.15K
485.30%103.2K
17.63K
Earnings from equity interest net of tax
Net income
-72.03%-42.32M
-3.57%-24.6M
-23.75M
Net income continuous operations
-72.03%-42.32M
-3.57%-24.6M
---23.75M
Noncontrolling interests
Net income attributable to the company
-72.03%-42.32M
-3.57%-24.6M
-23.75M
Preferred stock dividends
Other under preferred stock dividend
Net income attributable to common stockholders
-72.03%-42.32M
-3.57%-24.6M
-23.75M
Diluted earnings per share
-63.66%-0.155
1.04%-0.0947
-0.0957
Basic earnings per share
-63.66%-0.155
1.04%-0.0947
-0.0957
Dividend per share
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
(FY)Jun 30, 2024(FY)Jun 30, 2023(FY)Jun 30, 2022
Total revenue
Cost of revenue
Gross profit
Operating expense 55.70%56.31M19.39%36.16M30.29M
Selling and administrative expenses 170.43%5.48M-77.67%2.03M--9.07M
-General and administrative expense 170.43%5.48M-77.67%2.03M--9.07M
Research and development costs 45.53%45.78M66.45%31.46M--18.9M
Depreciation amortization depletion 52.29%153.07K117.33%100.51K--46.25K
-Depreciation and amortization 52.29%153.07K117.33%100.51K--46.25K
Other operating expenses 89.74%4.89M13.32%2.58M--2.28M
Operating profit -55.70%-56.31M-19.39%-36.16M-30.29M
Net non-operating interest income (expenses) 48.66%2.77M1,860.46%1.86M95.09K
Non-operating interest income 48.66%2.77M1,860.46%1.86M--95.09K
Other net income (expenses) 17.41%11.51M51.74%9.8M6.46M
Other non-operating income (expenses) 17.41%11.51M51.74%9.8M--6.46M
Income before tax -71.55%-42.03M-3.21%-24.5M-23.74M
Income tax 186.00%295.15K485.30%103.2K17.63K
Earnings from equity interest net of tax
Net income -72.03%-42.32M-3.57%-24.6M-23.75M
Net income continuous operations -72.03%-42.32M-3.57%-24.6M---23.75M
Noncontrolling interests
Net income attributable to the company -72.03%-42.32M-3.57%-24.6M-23.75M
Preferred stock dividends
Other under preferred stock dividend
Net income attributable to common stockholders -72.03%-42.32M-3.57%-24.6M-23.75M
Diluted earnings per share -63.66%-0.1551.04%-0.0947-0.0957
Basic earnings per share -63.66%-0.1551.04%-0.0947-0.0957
Dividend per share
Accounting Standards US-GAAPUS-GAAPUS-GAAP

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
AU
Overall
Symbol
Latest Price
% Chg

No Data